DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • Norway
  • /
  • Food, Beverage & Tobacco
Author Program NEWCreate Narrative
AKBM logo

Aker BioMarine ASA Stock Price

OB:AKBM Community·NOK 11.4b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 12 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

AKBM Share Price Performance

NOK 130.20
41.40 (46.62%)
​
NOK 124.91
Fair Value
NOK 130.20
41.40 (46.62%)
4.2% overvalued intrinsic discount
NOK 124.91
Fair Value
Price NOK 130.20
AnalystConsensusTarget NOK 124.91
AnalystHighTarget NOK 75.11
AnalystLowTarget NOK 48.40
Tue, 23 Jun 26
Fair ValueNOK 124.91
Share Pricen/a

AKBM Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value NOK 124.91 4.2% overvalued intrinsic discount

Analysts Lift Aker BioMarine Price Target on Improved Profit Margins and Key Customer Win

0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value NOK 75.11 73.3% overvalued intrinsic discount

Sustainable Demand Will Redefine Marine Omega-3 Nutrition

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value NOK 48.4 169.0% overvalued intrinsic discount

Rising Regulations And High Capital Demands Will Cripple Krill Supply

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AKBM logo
Aker BioMarine
4.2% overvalued intrinsic discount

Analysts Lift Aker BioMarine Price Target on Improved Profit Margins and Key Customer Win

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 23 Jun
Read Narrative
AKBM logo
Aker BioMarine
73.3% overvalued intrinsic discount

Sustainable Demand Will Redefine Marine Omega-3 Nutrition

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Published 14 Jul 2025
Read Narrative
AKBM logo
Aker BioMarine
169.0% overvalued intrinsic discount

Rising Regulations And High Capital Demands Will Cripple Krill Supply

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Published 15 Jul 2025
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystConsensusTarget
AKBM logo

AKBM: Higher Margin Contract Wins Will Support Stronger Future Upside

Fair Value: NOK 124.91 4.2% overvalued intrinsic discount
8 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystLowTarget
AKBM logo

Rising Regulations And High Capital Demands Will Cripple Krill Supply

Fair Value: NOK 48.4 169.0% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
AKBM logo

Sustainable Demand Will Redefine Marine Omega-3 Nutrition

Fair Value: NOK 75.11 73.3% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

High growth potential with mediocre balance sheet.

0 Risks
2 Rewards
View Full Analysis

Aker BioMarine ASA Key Details

US$227.2m

Revenue

US$124.9m

Cost of Revenue

US$102.3m

Gross Profit

US$112.3m

Other Expenses

-US$10.0m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Oct 29, 2026
-0.11
45.03%
-4.40%
150.7%
View Full Analysis

About AKBM

Founded
2006
Employees
258
CEO
Matts Johansen
WebsiteView website
www.akerbiomarine.com

Aker BioMarine ASA, a biotech innovator, develops and supplies krill-derived products for consumer health and wellness worldwide. It operates through three segments: Human Health Ingredients (HHI), Consumer Health Products, and Emerging Business. The Human Health Ingredients segment sells B2B krill oil supplements for humans under the Superba Krill brand; supplements for brain health under the LYSOVETA brand; and marine-origin DHA omega-3 from microalgae under the Revervia brand name, as well as advanced phospholipid technology under PL+ name. The Consumer Health Products segment sells processed and packaged krill, fish, and plants derived raw materials to retailers in the United States. The Emerging Business segment offers krill oil under Kori brand name. The company provides protein solutions under the Understory brand; biostimulants under KRBNX brand; and a therapeutic candidate based on omega-3 to manage and treat cardiometabolic diseases under CaPre brand name, as well as delivers circular products utilizing recycled industrial and marine plastic waste under AION name. Aker BioMarine ASA was founded in 2006 and is headquartered in Lysaker, Norway. Aker BioMarine ASA is a subsidiary of Aker ASA.

Recent AKBM News & Updates

User avatar
Narrative Update • Jun 23

AKBM: Higher Margin Contract Wins Will Support Stronger Future Upside

Analysts have slightly lowered their price target for Aker BioMarine to NOK 124.91, reflecting modestly revised assumptions around long term revenue growth, profit margins, and a somewhat lower future P/E multiple. What's in the News for Aker BioMarine Aker BioMarine ASA secured a new contract for the supply of Lysoveta, with a contract value of about US$4 million in 2026 and expectations for higher volumes in 2027, according to a client announcement.

Recent updates

No updates

Aker BioMarine ASA Competitors

MOWI logo

Mowi

Symbol: OB:MOWI
Market cap: NOK 108.5b
ORK logo

Orkla

Symbol: OB:ORK
Market cap: NOK 87.6b
SALM logo

SalMar

Symbol: OB:SALM
Market cap: NOK 79.2b
BAKKA logo

P/F Bakkafrost

Symbol: OB:BAKKA
Market cap: NOK 26.5b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide